Genetic Technology (Precision Breeding) Bill (First sitting)

Deidre Brock Excerpts

Committee stage
Tuesday 28th June 2022 Public Bill Committees

[The Chair]

Thank you. I call the SNP spokesperson, Deidre Brock.

[Deidre Brock (Edinburgh North and Leith) (SNP)]

Q Thank you, Mr Stringer. Mr Exwood, the Minister asked you about your members’ views. Have your members been surveyed on the Bill, and if so, what did they say? Is there a difference in views on this matter between, say, organic farmers or small family farms, and larger farms?

David Exwood: Absolutely. We run our consultation process and work up our policy as one organisation that brings in all sectors—organics being one of them. I think everybody recognises the advantages of technology; everybody recognises the benefits that breeding brings. That goes for organic farmers and smaller farmers as well as large farmers. We have to co-exist alongside organic farming in all circumstances—we are very clear about that. We do not see that as a challenge; we already run slightly separate systems and it does not significantly alter business in any way.

The key element of the Bill for small farmers is that it is drafted in such a way as to make it as widely available as possible. It needs to be open to as many farmers as possible—that is how it will bring the most benefit. Breeding actually brings benefit to all farmers, and a good variety of wheat or sugar beet, say, is something that all farmers will benefit from, regardless of their size.

[Deidre Brock]

Q Do you agree that sufficient safeguards can be put in place to protect organic farms from what they might see as a sort of contamination—if I can call it that—from those products?

David Exwood: Yes, I do. As I said, we run existing codes, and conventional and organic already co-exist. This does not change that in any way. We have to make sure that we are able to do that. There has to be a co-existence—I am very happy about that—which is a key part of our policy and our ask. I do not see the Bill as being a challenge to that.

Dr Ferrier: The market for organic versus conventional or other systems currently enables segregation for different specifications that the market might ask for. We see that continuing to run as it does at the moment. When a buyer has particular specification, there is certification for organics. As we understand it, the certification for organics would not currently allow the use of precision bred organisms. Obviously, that could change, allowing for segregated supply chains, just as with food-grade versus industrial-grade oilseed rape, or with sweetcorn and forage maize, which are kept apart.

If you are getting a new variety of a particular crop, for example, and you grow a crop for seed multiplication purposes, the high-purity requirements for that seed are there and are managed within the supply chain. We see that continuing to apply for organic farmers.

[John Howell (Henley) (Con)]

Q Earlier, you were asked about our relationship with the EU on this matter, and you mentioned progress in precision breeding across the world. How does that fit together, where is most of the research taking place, and which countries should we look at to make comparisons with the UK?

Dr Ferrier: Certainly, the most recent development in countries reviewing their legislation, and one that I think would be really useful for you to look at, is what Health Canada, the Canadian authority, has done. It has recently reviewed its legislation and put out some technical guidance. The key thing is that it confirms that precision bred organisms do not pose any additional safety risks compared with conventionally bred plant varieties. That is driving Canada’s regulatory process. It is not proposing different authorisation and risk-assessment processes. It does not believe that that would add any significant benefit for consumers or the environment, because the science does not show any additional risks—that is very similar to the European Food Safety Authority opinion from the end of November 2020.

Argentina is certainly a very interesting case. Since it has put in place proportionate and enabling regulations—such as those that the Government propose in this Bill—it has seen a real increase in the number of small and medium-sized enterprises and public-good breeding R&D activities taking products through that regulatory process, so that it is not just the preserve of the largest companies that are able to pay for and absorb any uncertainty in a less ideal or dysfunctional regulatory process.

Japan is another example of where a product—a tomato—has been through that process. In countries that put in place proper regulation, the actual process is functional and works well for the companies. Those countries then see investment in R&D and into commercial companies. That is bringing through the products. South America, North America and Japan are investing in this. It is interesting to see how quickly the science develops into commercial opportunities once the regulations are right.

David Exwood: The challenges that we face as farmers in the UK—sustainability, climate change and so on—are the challenges faced by farmers across the world, and we are all looking for solutions to those problems. It is interesting that across the world, there is a move on this technology, which we are seeing quite widely. That is because everybody is looking for answers and solutions to the challenges that we all face.

--- Later in debate ---

[The Chair]

You are back, Professor Henderson. We move on to the SNP spokesperson, Deidre Brock.

[Deidre Brock]

Q The Scottish Government have stated that they will wait to assess the outcomes of the EU consultation on gene editing and GM. Some feel that the UK Government are rushing ahead with the Bill, potentially to the further detriment of trade with the EU. The UK Government are clearly very confident in the evidence they have received on this, because they are pushing ahead with it. Will you tell us about the peer-reviewed evidence that the Government are relying on that supports the claim that gene editing can make farming sustainable and environmentally friendly? Can you point to that evidence?

Professor Henderson: I can. There is a very wide range of peer-reviewed literature that demonstrates the benefits that can arise from the use of gene editing for precision breeding, for building better crops. The list is long and I would be happy to share a long list of some of the references. There was a review paper published in Nature in 2019 that I often refer back to, which summarises the many routes by which we can use gene editing to enhance crops.

I am wary of time, but I could talk at some length about the different sorts of crops that might be beneficial in this context. There is also an extensive peer-reviewed literature that demonstrates the safety of these technologies and the fact that the unintended consequences through precision breeding are generally lower than those through traditional breeding, and particularly some of the more extreme mutagenic forms of precision breeding. There is very extensive scientific literature.

You started your question by pointing to the differences of opinion politically on the different sides of the national borders within the United Kingdom. I should say that scientifically, there is not a difference of opinion as you change nations in the country and certainly leading scientists in this sector in Wales and Scotland have also been very instrumental in the peer-reviewed literature that I have mentioned, and they agree with the sense of direction of this Bill, although their political leaders do not.

[Deidre Brock]

Q And the potential impact on trade with the EU?

Professor Henderson: As a scientist, trade is less my area of expertise, but to some extent you could argue that this Bill would enable more trade, because it will enable better crops and more crops to be produced, and therefore they could be more readily traded overseas, giving more market opportunities for UK farmers and markets. [Inaudible.] Therefore, I do not see an immediate problem with any trade with the EU, either.

It is also true to say, as I believe your previous—[Inaudible.] Sorry, are you still there?

[The Chair]

We are. We missed a little towards the end there, Professor.

Professor Henderson: I am sorry; if it happens again, I will switch wi-fi on to my phone. I do apologise.

I was saying that, from an EU perspective, the final thing to say is that the EU itself is of course consulting on changing the law in a way similar to the way that we are considering, and it is quite likely to change on the same timescale that we will be producing marketable crops.

--- Later in debate ---

[Daniel Zeichner]

Q All that is very interesting and very good, but I do not actually see that this is covered in the Bill as it stands. This is all going to have to follow through secondary legislation, is it not?

Professor May: That is correct. At the moment, part 3 of the Bill encompasses the direction of travel, but not the details. That is something we are working on at the moment.

[Deidre Brock]

Q Food Standards Scotland produced a paper in March of this year that pointed out potential for regulatory divergence between the four nations of the UK and that the Bill could result in Ministers in England taking decisions on the approval of genome-edited food and food products with little or no involvement from Food Standards Scotland or, indeed, Ministers in Scotland. It is an independent authority, as you know. Can you tell us how that relationship will be approached and managed, if the Bill becomes an Act?

Professor May: Happily, I am here as a scientist, so I can say that, scientifically, we have an extremely close working relationship with FSS and other regulators around the world, but the closest is with FSS.

If I give an example, at the moment, risk assessments that we might do in FSA are shared very closely with FSS. All that process is done together. Often we are using the same sets of experts—for example, to provide information. Once the risk assessment is done, it passes to a risk management process. I cannot think of an example where there is a difference in the risk assessment part between nations, because the science is the science.

Where there are sometimes differences is in the risk management area. A current example is raw drinking milk, because the science around the risks of drinking such milk is the same, but England and Scotland have different views on how much risk is acceptable. Under this framework, I would fully intend that we would share all the science around the risk assessments of a precision-bred product. Ultimately, though, the decision on a risk management basis and whether to authorise it would fall to Ministers in each of the individual countries.

[Deidre Brock]

That is helpful. Thank you.

[Ruth Jones]

Q Thank you for your time this morning, Professor May. We heard from a previous witness that the EU is likely to develop its work on gene editing along similar timescales. Given the need to share information, how will the FSA and the European Food Safety Authority share information as we go down this path?

Professor May: Previously, prior to Brexit, everything was handled at the European level. As I just mentioned, we share informally the scientific advice, which is very international. Often the people who are providing evidence for a risk assessment are the same people—they may not even be within the EU, but wherever that expertise is available in the world—so there is quite a lot of sharing at that level. Currently, our only formal arrangement with the EU on food safety is around alerts. An alert for a food safety issue that may have an impact on the UK is passed to us, but something that affects countries outside and has no impact on the UK would not necessarily be shared.

I think all of us hope that there will be a reciprocal arrangement for sharing information in future. It is in everyone’s interest to share as much evidence and data as possible, but that is obviously not in my gift to control. There is recognition in the EU that the current GM framework is not fit for purpose for these kinds of products, so the process is already rolling in the EU to look at how it might be changed. How long that will take, and what the outcome might be, will obviously be very different. I would anticipate that it is going to take longer than it will in the UK to get resolution on that.

[Ruth Jones]

Q You mentioned alerts. Obviously, nobody wants to leave it until there is an alert situation, but what about developing more formal mechanisms as we go forward, rather than relying on the good will of scientists?

Professor May: Sitting here as a scientist, obviously I hope very much that there will be good sharing. As I said before, it is in everyone’s interest to share the best science and the best evidence around this. Happily, building those relationships is not in my purview to organise, but I hope that there will be sharing, particularly around the horizon-scanning function. For us as a regulator, it is really critical to think about not just what is on our desks now, but what will be there in two, three or five years’ time. What is the science that we will need to assess the potential risks of products that I have not even thought of yet? Collaborative agreement around what might be coming down the road is really critical for all of us.

[Deidre Brock]

Q Something occurred to me when I was looking at the Bill again last night. Do you feel that you have sufficient capacity to be able to cope with the extra responsibilities that you are taking on? Have the Ministers given you further guarantees that you will be supported in that?

Professor May: That is a very good question. It is hard to predict based on the estimation of what might be coming to our desks. On the one hand, the Bill will remove a tranche of products that would otherwise have been assessed as GM products. We already regulate GM products, and there is the capacity. On the other hand, the purpose of the Bill is to stimulate development in this area, so we may end up with a lot more applications, in which case we are going to need additional resource. We have taken steps in that direction, including recruiting independent experts in this area to provide scientific expertise, but if there were a large volume of applications needing consideration, we would need additional support.

[Kate Green (Stretford and Urmston) (Lab)]

Q Good morning, Professor May. To return to the discussion that we were having a few moments ago about information for the consumer, to what extent does the Food Standards Agency have a role in providing general public information and education? If that is not the role of the FSA, who should be doing it and how important is it?

Professor May: Our statutory mandate is to protect consumers and represent their interests as they pertain to food. That includes a communication role ranging from allergy alerts and food withdrawals through to a more nuanced understanding of the food system—food security, food poverty and those kinds of questions. At the moment, we do a fair bit of public communication around issues that we know consumers are interested in. Precision breeding, on which we have done some work, is a good example. An explainer on what genome editing and precision breeding are, and what impact they might have, is available on our website, for example.

We do a limited amount of work with schools—particularly in some regions of the UK—mostly on food hygiene. There is an opportunity to do more to explain to people the honest truth about food, and to help them to make decisions about safety and their purchasing decisions in that space. There is always room to do more. There is a lot of consumer interest in this class of foods, and I anticipate that we will do more to make sure that people have the facts about it that they will want.

--- Later in debate ---

[Daniel Zeichner]

Thank you. I will leave it there for the moment.

[Deidre Brock]

Q The Scottish and Welsh Governments have clearly stated their intention at present for precision bred organisms to be regulated as GMOs. How will ACRE’s advice on releases to the environment take account of the fact that the Welsh and Scottish Governments currently have a different approach from Westminster on this?

Professor Dunwell: Well, we realise that the jurisdiction is different. We have observers at ACRE meetings from the devolved authorities—not at every meeting, but they are clearly invited to attend, and some of them do. They can add their own input into the discussions, even though it will not apply within their jurisdiction. Then of course we have the fact that much of the good science goes on at the James Hutton Institute, the Roslin Institute and elsewhere. Those are world-class centres of science doing this type of research. I am sure that among those scientists there is an intrinsic frustration about the political environment that exists, but I am not going to comment on the policy at that level. ACRE as a committee had sessions in Edinburgh some three or four years ago, and we have spoken to the relevant committees directly. I was part of those discussions.

[Deidre Brock]

Q Is there a counterpart for ACRE in the EU Commission that you have regular dealings with? Obviously, the devolved Governments—certainly, the Scottish Government—are waiting to hear the outcome of the consultation that the EU is undertaking on this area. Can you tell us a little about how that is working currently?

Professor Dunwell: Under the EU system a lot of the discussion was part of EFSA. Obviously it is different now, but in those days it fed back information to ACRE. Even though we have kind of split, we still take account of and look at the EFSA reports on a regular basis. We keep up to date with the discussions in the whole area of science looking forward, because it is our responsibility to make sure that ACRE is not just an isolated UK silo. We have those reports and there still are UK people who sit on EFSA committees, even though we are not part of the official system. It has not disqualified the scientific input from the UK into the EU, which is an interesting element in its own right.

[Deidre Brock]

Q Yes, indeed. I am glad to hear we are not completely cut off. That is great. Getting back to genetically engineered crops, some say that when they are grown on a commercial scale, the risks of escape and contamination are greater. Is that something that you agree with?

Professor Dunwell: Well, it is the terminology “escape”. Perhaps it comes from releasing things into the environment, which has some implication to it, but there is no evidence that any existing genetically modified things that are on the market have any greater impact on the environment either through pollen dispersal or propagule dispersal than any existing variety has. Just because it is genetically modified or, in the future, gene edited, it will not intrinsically expand the danger of gene contamination, which is often an objection.

[Deidre Brock]

Q So the fact that these are expanded and grown on a commercial level will not have—

Professor Dunwell: It is not relevant. There is no evidence for that.

[Deidre Brock]

Q Okay, thank you. Can you tell me a little bit about the old-style GMOs and whether all of them would be included in the definition of a precision bred organism?

Professor Dunwell: No, they would be excluded. You have taken a gene or genes, and you accumulate the numbers of genes. Some of the things that are being grown in the States now might have eight or 10 transgenes —separate genes—all inserted into the same variety. That is completely different from what we are discussing today, which is minor changes that are much more equivalent to forms of mutation that have existed for ever. The domestication of crops relied on mutations, but we did not know at the time what they were. Agriculture and what you eat today is a product of natural mutation.

[Deidre Brock]

Q Forgive me, but could you expand a little on what you said about the US and the insertion of seven different—sorry, I am not a scientist.

Professor Dunwell: There are lots of maize varieties that have been proposed and are grown commercially in the States over large areas. Initially, 20 or so years ago, they just had one or two genes, which were to do with insect resistance or herbicide tolerance, but over time the numbers of genes have been pyramided together, either by introducing them all at once or by crossing together a transgenic plant that has one insert and one that has two, so there are varieties now with six, eight or 10 different genes from different sources in one commercial product.

[Deidre Brock]

Q So that has developed over that 20-year period.

Professor Dunwell: Yes, and it has been done by—

[The Chair]

Order. May I just say that there are a number of people who wish to speak? If there is time at the end, I will come back to you, Deidre. I call Andrew Bowie.